Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (October 2019)
15 slides from Arbutus Biopharma's investor presentation, Oct 3, 2019
Slide 1: Singularly Focused on HBV
Singularly Focused on HBV October 2019 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this pur
Slide 3: Investment Highlights
Investment Highlights Singular therapeutic focus - curing chronic Hepatitis B Virus (HBV) Team with Significant antiviral Broad Financial Goal unmet medical expertise & HBV Position Functional need in HBV proven track Portfolio Cure record Global HBV Applying HBV assets $95M cash at 6/30/19 Goal of
Slide 4: Proven Leadership Team
Proven Leadership Team William H. Collier Michael J. Sofia, PhD Gaston Picchio, PhD Successful track records President and CEO Chief Scientific Officer Chief Development Officer in both the discovery, development, and commercialization of multiple antivirals: sofosbuvir, etravirine, rilpivirine, tel
Slide 5: HBV Lifecycle Illustrates Key Points for Intervention
HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1 –Nucleoside Analogue 2 –Capsid Inhibitor 3 –AB-729 3 –RNA Destabilizer 2 3 1 2 NASDAQ: ABUS www.arbutusbio.com
Slide 6: Keys to Therapeutic Success
1 Reduce/Suppress Keys to Viral DNA & Antigens Therapeutic Block Replication . NA . Capsid Inhibitor . RNAi Success . RNA Destabilizer Block HBsAg . RNAi . RNA Destabilizer Suppress HBV DNA Address cccDNA and viral antigens . Capsid Inhibitor . cccDNA inhibitor Leading to an Reawaken host HBV CURE i
Slide 7: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Lead Op Development IND Enabling Healthy Subjects HBV Subjects Phase II HBV DNA Suppression AB-506 Development discontinued Capsid Inhibitors 3rd gen HBsAg Reduction RNAi AB-729 AB-452 HBV RNA Destabilizers 2nd Gen Immune Reawakening PD-L1 1st gen cccDNA 1st gen NASDAQ:
Slide 8: Capsid Inhibitor: Blocking HBV Replication
Reduce Capsid Viral DNA & Antigens Inhibitor: Blocking HBV HBV Replication Replication cccDNA Formation Driving HBV DNA to undetectable, in the serum and Reduced HBsAg in the liver is a key to therapeutic Immuno-modulation success in HBV Reawaken Immune Response NASDAQ: ABUS www.arbutusbio.com 8
Slide 9: AB-506 Capsid Inhibitor: Decision to Discontinue Development
AB-506 Arbutus Announces Decision to Discontinue Development of Capsid AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Inhibitor William H. Collier, President and Chief Executive Officer of Arbutus, stated, “We have observed two cases of acute hepatitis in our Phase 1a 28-d
Slide 10: Driving Down HBsAg Is A Key to HBV Therapeutic Success
Reduce/Suppress Driving Viral DNA & Antigens Down HBsAg Is A Key to HBV Replication HBsAg Therapeutic cccDNA Formation Success in HBV HBsAg is responsible for immune exhaustion Reduced HBsAg Replication inhibitors do not block HBsAg production Immunotherapy Reawaken/Boost Immune Response NASDAQ: ABU
Slide 11: AB-729 RNAi Therapeutic
AB-729 RNAi Single trigger RNAi agent targeting all HBV transcripts Therapeutic Inhibits HBV replication and lowers all HBV antigens . Potent HBsAg reduction in preclinical models Pan-genotypic activity across HBV genotypes Proprietary GalNAc-conjugate delivery technology provides Duration of HBsAg
Slide 12: AB-729 In Vivo Single Dose Response & Duration
AB-729 In Vivo Single 4 Dose Response 3 Saline & Duration 1 mg/kg 2 3 mg/kg 9 mg/kg Clear dose response Mean (n=5) ± SD 1 in AAV mouse model (Log IU/mL) Serum HBsAg Serum Achieves maximum HBsAg reduction possible 0 in this model LLOQ -1 Duration supports 0 2 4 6 8 10 a clinical dosing frequency 1 do
Slide 13: Small Molecule HBV RNA Destabilizers
Small Molecule HBV RNA Destabilizers HBV RNA reduction leads to interference in viral gene AAV mouse model expression, DNA replication, and virion assembly PO dosing Dose-dependent reduction in HBsAg HBsAg reduction correlates with reductions in liver HBV RNAs NASDAQ: ABUS Gotchev, D., et al., AASLD
Slide 14: AB-452 and RNA Destabilizer Program
AB-452 and RNA Destabilizer Program Multiple evaluations underway to support AB-452 and RNA destabilizer program next steps Completed Ongoing IND enabling studies and . In vitro target engagement 28 day toxicology and target-based cell viability evaluations Multiple AB-452 mechanism of action st
Slide 15: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Lead Op Development IND Enabling Healthy Subjects HBV Subjects Phase II HBV DNA Suppression AB-506 Development discontinued Capsid Inhibitors 3rd gen HBsAg Reduction RNAi AB-729 AB-452 HBV RNA Destabilizers 2nd Gen Immune Reawakening PD-L1 1st gen cccDNA 1st gen NASDAQ:
Arbutus Biopharma — Investor Presentation (October 2019) on 6ix